Why the study?
Does ticlopidine affect platelet function, blood coagulation, and safety in healthy volunteers?
Does ticlopidine affect platelet function, blood coagulation, and safety in healthy volunteers?
Ticlopidine demonstrates safe and effective suppression of platelet aggregation in healthy volunteers, supporting its potential as an antithrombotic agent.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; hypothesis-generating for ticlopidine as an antithrombotic agent in patients.
A new antithrombotic agent, ticlopidine was administered to 6 healthy volunteers to investigate its effects on platelet function and blood coagulation as well as its safety.No problem was noticed in the safety of the drug when 500 mg was orally administered every 12 hours for 3 days. Blood concentration of the drug reached the peak level 2 hours after administration and it was not detected in blood 8 hours after administration. It was observed that ticlopidine exerted longlasting suppressive effect on platelet aggregation and adhesiveness, but it did not show any effect on the blood clotting and fibrinolysis systems.
No takes yet. Share an insight, caveat, or question.
Ebihara et al. (1978) studied Healthy volunteers (n=6). Ticlopidine vs. Baseline (pre-administration) was evaluated on Platelet aggregation and adhesiveness (p=<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: